Use of antidiabetic drugs in the US, 2003–2012 C Hampp, V Borders-Hemphill, DG Moeny, DK Wysowski Diabetes care 37 (5), 1367-1374, 2014 | 246 | 2014 |
Cancer risk associated with lorcaserin—the FDA’s review of the CAMELLIA-TIMI 61 trial J Sharretts, O Galescu, S Gomatam, E Andraca-Carrera, C Hampp, ... New England Journal of Medicine 383 (11), 1000-1002, 2020 | 127 | 2020 |
Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study S Toh, C Hampp, ME Reichman, DJ Graham, S Balakrishnan, F Pucino, ... Annals of internal medicine 164 (11), 705-714, 2016 | 123 | 2016 |
Use of prescription antiobesity drugs in the United States C Hampp, EM Kang, V Borders‐Hemphill Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (12 …, 2013 | 118 | 2013 |
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications C Hampp, TL Kauf, AS Saidi, AG Winterstein Archives of pediatrics & adolescent medicine 165 (6), 498-505, 2011 | 110 | 2011 |
Emergency hospitalizations for unsupervised prescription medication ingestions by young children MC Lovegrove, J Mathew, C Hampp, L Governale, DK Wysowski, ... Pediatrics 134 (4), e1009-e1016, 2014 | 88 | 2014 |
Cost-utility analysis of rimonabant in the treatment of obesity C Hampp, AG Hartzema, TL Kauf Value in Health 11 (3), 389-399, 2008 | 75 | 2008 |
Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study AG Winterstein, CA Knox, P Kubilis, C Hampp JAMA pediatrics 167 (12), 1118-1124, 2013 | 61 | 2013 |
Use of sodium–glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis C Hampp, RS Swain, C Horgan, E Dee, Y Qiang, SK Dutcher, A Petrone, ... Diabetes Care 43 (1), 90-97, 2020 | 46 | 2020 |
Sentinel modular program for propensity score–matched cohort analyses: application to glyburide, glipizide, and serious hypoglycemia M Zhou, SV Wang, CE Leonard, JJ Gagne, C Fuller, C Hampp, ... Epidemiology 28 (6), 838-846, 2017 | 39 | 2017 |
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007 JM Lawrence, SE Andrade, LA Avalos, SJ Beaton, VY Chiu, RL Davis, ... Obstetrics & Gynecology 121 (1), 106-114, 2013 | 39 | 2013 |
A systematic review of pregnancy exposure registries: examination of protocol‐specified pregnancy outcomes, target sample size, and comparator selection K Gelperin, H Hammad, K Leishear, ST Bird, L Taylor, C Hampp, L Sahin Pharmacoepidemiology and Drug Safety 26 (2), 208-214, 2017 | 37 | 2017 |
Impact of the 2014 American Academy of Pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants LR Krilov, J Fergie, M Goldstein, L Brannman American journal of perinatology 37 (02), 174-183, 2020 | 36 | 2020 |
Data linkage in pharmacoepidemiology: a call for rigorous evaluation and reporting NL Pratt, CD Mack, AM Meyer, KJ Davis, BG Hammill, C Hampp, ... Pharmacoepidemiology and drug safety 29 (1), 9-17, 2020 | 36 | 2020 |
Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida C Hampp, AS Saidi, AG Winterstein The Journal of pediatrics 156 (6), 953-959. e1, 2010 | 32 | 2010 |
Prospective postmarketing surveillance of acute myocardial infarction in new users of saxagliptin: a population-based study S Toh, ME Reichman, DJ Graham, C Hampp, R Zhang, MG Butler, A Iyer, ... Diabetes care 41 (1), 39-48, 2018 | 27 | 2018 |
Patient understanding of drug risks: an evaluation of medication guide assessments CA Knox, C Hampp, M Willy, AG Winterstein, G Dal Pan Pharmacoepidemiology and drug safety 24 (5), 518-525, 2015 | 27 | 2015 |
Enrollment and retention in 34 United States pregnancy registries contrasted with the manufacturer’s capture of spontaneous reports for exposed pregnancies ST Bird, K Gelperin, L Taylor, L Sahin, H Hammad, SE Andrade, ... Drug safety 41, 87-94, 2018 | 25 | 2018 |
An algorithm to identify preterm infants in administrative claims data E Eworuke, C Hampp, A Saidi, AG Winterstein Pharmacoepidemiology and drug safety 21 (6), 640-650, 2012 | 24 | 2012 |
Effectiveness of palivizumab prophylaxis in infants and children in Florida AG Winterstein, C Hampp, A Saidi Pharmacoepidemiology and drug safety 21 (1), 53-60, 2012 | 24 | 2012 |